August 25, 2025 — Propanc Biopharma, Inc. (Nasdaq: PPCB) shared a shareholder update that included recent corporate developments and a forecast for 2025/26.
Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study in 2026.
The study will involve 30 – 40 advanced cancer patients suffering from malignant solid tumors and is designed to identify the maximum tolerated dose (MTD).
The Company recently closed an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol, “PPCB”.
Propanc expanded its management team and Board of Directors with the appointment of a Chief Financial Officer and two Non-Executive Directors on August 13 and 14 respectively.
PRP clinical development activities include validation of a pharmacokinetics method, regulatory documentation for the upcoming Phase 1, FIH study, and finished product manufacture of the PRP formulation for the upcoming clinical study.
Once completed, the goal is to submit a clinical trial application for the Phase 1, FIH study by the first half of 2026 at the Peter Mac Cancer Center.
James Nathanielsz, Chief Executive Officer, +61-3-9882-0780, info@propanc.com
Source: Propanc Biopharma, Inc.
